Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 22, 2026.

Oxidative Stress: A Major Player in Cerebrovascular Alterations Associated to Neurodegenerative Events

Cristina Carvalho, Paula I. Moreira

Frontiers in Physiology · 2018 · Review

doi:10.3389/fphys.2018.00806

Abstract

The brain is one of the most exquisite organs in the body with high metabolic demands, and requires a tight regulation of the surrounding environment. This tight control is exerted by the neurovascular unit (NVU) comprising different cell types, where endothelial cells play the commander-in-chief role. Thus, it is assumable that even slight perturbations in NVU might affect, in some cases irreversibly, brain homeostasis and health. In this line, recent findings support the two-hit vascular hypothesis for neurodegenerative conditions, where vascular dysfunction underlies the development of neurodegenerative diseases, such as Alzheimer's disease (AD). Knowing that endothelial cells are rich in mitochondria and nicotinamide adenine dinucleotide phosphate (NADPH) oxidases, two major reactive oxygen species (ROS) sources, this review aims to gather information on how oxidative stress is in the front line of vascular alterations observed in brain aging and neurodegenerative conditions, particularly AD. Also, a brief discussion about the therapeutic strategies aimed to protect against cerebrovascular diseases is included.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 22, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

The brain integrates and regulates several central and peripheral signals to maintain body homeostasis. So, it is not surprising that the brain is an organ with a high energy demand, although it represents only 2% of the body weight. In fact, it is widely known that proper neuronal activity entails high amounts of energy. However, the capability of the brain to store energy is very reduced, requiring a constant supply of energy substrates, namely glucose, through blood flow to fulfill its energy needs. For that reason the brain receives about 15% of cardiac output and accounts for 20% of total body oxygen consumption. At this point, it is worth mentioning the neurovascular coupling, where neurons, glial cells and blood vessels communicate to each other to regulate cerebral blood flow (CBF) and vessels permeability depending on location and neuronal activity in order to efficiently maintain energy substrates supply to satisfy the metabolic needs. Cerebral blood vessels comprise unique properties forming the blood–brain barrier (BBB), a physical barrier that permits the passage of water, some gases and lipophilic molecules by passive diffusion and the selective transport of certain molecules (e.g., glucose) and protects against external toxins and pathogens. Thus, even slight alterations in BBB properties can be responsible for the onset/progression of neurological diseases. From all the BBB constituents (endothelial, mural and glia cells, astrocytes and macrophages), endothelial cells that form blood vessels, play a major role in BBB proper functioning. Blood vessels control the influx and efflux transport allowing, for example, the entry of glucose and amino acids from the blood into the central nervous system (CNS) and the removal of specific waste products from the CNS into the blood. More recently,, performed a mapping of brain microvessels obtained from two healthy human adult brain samples and found that in certain brain areas microvessels density is higher than others, which can reflect the different susceptibilities to vascular damage. Even slight alterations in brain vasculature can underlie different neurodegenerative events. Indeed, it is widely described that conditions interfering with brain vasculature, such as stiffening of cerebral arteries or increased vessel tortuosity, caused by diabetes and hypertension among other conditions, can induce BBB breakdown underlying the development of neurodegenerative conditions such as Alzheimer’s disease (AD). It is also known that in many cases BBB integrity is deeply affected by oxidative stress. In fact, increased reactive oxygen species (ROS) production contribute to endothelium dysfunction and increased permeability of BBB. These alterations are mainly attributed to the redistribution and/or altered expression of critical tight junction proteins such as claudin-5 and occludin.

Although it is widely accepted that vascular changes play a crucial role in neurodegenerative diseases, none of the available therapies are effective when translated to clinical trials revealing some gaps in the mechanisms behind the vascular and tissue brain changes under pathological conditions. Thus, studies aimed to develop new non-invasive techniques to better understand why and when changes occur bring a new hope for the treatment of conditions characterized by cerebrovascular alterations. In the next section we will discuss the role of oxidative stress in brain vascular alterations putting the focus on mitochondria and nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (Nox).

Major Players in Vascular Oxidative Stress

It is widely known that cells homeostasis depends on the regulated levels of ROS. Low/moderate levels of ROS can act as signaling molecules, which are crucial to maintain normal cells function, while uncontrolled generation of ROS causes oxidative damage contributing to cells dysfunction and damage.

Physiological ROS levels can play important roles in cerebral vasculature. Studies performed in animal models show that ROS can contribute to the regulation of brain perfusion through their action in vascular tone control. Indeed, physiological levels of ROS play a major role as cerebral vasodilators (Figure 1). For example, it has been shown that the addition of NADPH, the substrate for Nox, in cerebral vessels in vitro and in vivo cause hydrogen peroxide (H2O2)-dependent vasodilatation.

The neurovascular unit (NVU), containing neurons, astrocytes, pericytes, microglia and endothelial cells, is equipped with a powerful antioxidant defense systems that include glutathione (GSH), glutathione peroxidase, glutathione reductase, superoxide dismutase and catalase. GSH in particular has been shown to play an important role in the maintenance of BBB integrity (Figure 1). Also, the nuclear factor erythroid 2-related factor 2 (NRF2) seems to play a major defense role by modulating microglial dynamics, by protecting astrocytes and neurons from toxic insults and by regulating the expression of antioxidant enzymes. Additionally, NRF2 induces secondary defense proteins via interaction with the antioxidant response element (ARE) in the promoter region of target genes (Figure 1). Interestingly, astrocytes have a higher capability of efficiently increase GSH and ARE-linked gene expression, which allows astrocytes to be more protected than neurons against moderate levels of oxidative stress.

A failure in the ability of NVU cells to maintain the proper balance between ROS production and their neutralization causes the disruption of NUV and brain homeostasis predisposing to neurodegenerative conditions. It has been shown that following an injury microglia and astrocytes produce high levels of ROS via Nox, which seem to have harmful effects in the expression of important molecules involved in BBB integrity (e.g., ZO-1, claudin-5 and occluding). Pericytes, which are in close proximity to endothelial cells, play a vital role in the integrity of BBB. Under pathological conditions, pericytes are highly susceptible to oxidative stress resulting from overproduction of mitochondrial ROS. Moreover, it has been demonstrated that ROS production by activated microglia causes pericytes apoptosis. However, there is a lack of information regarding the role of ROS in pericytes under physiological conditions. Endothelial cells signaling seems to be crucial in the regulation of NVU proper functioning with increased ROS formation playing a major role in the alteration of NVU function and coupling.

It was also shown that ROS-induced changes in microcirculation can have profound implications in brain vascular pathophysiology due to alterations in blood flow resistance and, consequently, in regulation of blood pressure (Figure 1). Both superoxide (O2•-) and H2O2 are able to cause both relaxation as well as contraction of cerebral blood vessels depending on the concentration and presence of other species. In fact, oxidative stress can impair cerebral vascular function via the disruption of endothelium-dependent nitric oxide (•NO) signaling (Figure 1). It is widely described that the reaction of O2•- with •NO leads to a decrease in •NO bioavailability and, consequently, a decrease in its vasodilator, anti-proliferative, and anti-inflammatory properties. Furthermore, increased levels of H2O2, a common vasodilator in cerebral circulation, can act as a pro-apoptotic agent in cerebral vascular cells (Figure 1). Increased levels of ROS can also lead to an increase in Rho kinase signaling interfering with endothelial nitric oxide synthase (eNOS) expression and activity, affecting •NO production (Figure 1).

Considering vascular cells, there are several ROS sources such as mitochondrial electron-transport chain, cyclooxygenases (COXs), lipoxygenases, cytochrome P450 reductases, xanthine oxidase, nitric oxide synthase (NOS) and Nox. However, in this review, we only discuss mitochondria and Nox, both of them widely described as main producers of ROS either in physiological and pathological conditions in endothelial cells.

Mitochondria: More Than an Energy Producer

Reporting to the history of biology evolution, mitochondria are described as organelles derived from aerobic bacteria that in ancient times invaded proto-eukaryotic cells as parasites. From there, a symbiotic relationship evolved with mutual benefits and mitochondria became intracellular organelles. Although mitochondria are widely described as energy producers through the highly conserved oxidative phosphorylation (OXPHOS) process, nowadays the role of mitochondria reached substantially higher importance in cell homeostasis due to their involvement in several vital processes such as cell growth and differentiation, cell cycle control and death, intermediary metabolism, calcium (Ca2+) homeostasis and signaling, and apoptosis.

However, mitochondrial energy production can be a double-edge sword. Indeed, OXPHOS is not 100% efficient and during this process an electron leak occurs between mitochondrial complexes leading to the production of ROS such as O2•-, •NO, hydroxyl radical (HO•), peroxynitrite (ONOO-), and H2O2. As previously mentioned, low/moderate ROS levels exert a beneficial role by activating protective mechanisms. However, when ROS levels reach critical values they lead to oxidative stress and activate anomalous signaling mechanisms that can lead to cells degeneration and death.

Brain endothelial cells seem to possess a number of mitochondria higher than that observed in peripheral endothelial cells. However, in comparison with other cell types with higher energy requirements, mitochondria content in endothelial cells is modest. In rodent models, mitochondria compose 2–6% of the cell volume as opposed to 28% in hepatocytes and 32% in cardiac myocytes. These observations support the idea that mitochondria is not a major source of energy in brain endothelial cells. In fact, several studies support the idea that brain endothelial cells obtain a large proportion of their energy from anaerobic glycolytic metabolism of glucose. Actually, mitochondria are more likely to serve primarily as essential signaling organelles in the vascular endothelium.

The activation of mitochondria by physiological stimuli or pharmacological agents leads to the liberation of vasoactive factors by the endothelium, which exert a major role in the modulation and maintenance of BBB integrity and brain homeostasis. Moreover, it is far known that aging leads to a decrease in mitochondria number in cerebral endothelial cells associated with the loss of BBB integrity. The BBB high demand of mitochondrial activation comes with a price, the prospect for an increased ROS production that in physiological conditions is regulated by antioxidant enzymes such as glutathione reductase, manganese superoxide dismutase, catalase, among others. Additionally, it has been demonstrated that vascular endothelial growth factor (VEGF) exerts its functions in endothelial cells migration through mitochondrial ROS, a process involved in several physiological processes such as wound healing and vascular repair. Moreover, studies in human coronary resistance arteries showed that mitochondrial ROS are involved in endothelium regulation of vascular homeostasis. In the same study, the authors reported that mitochondrial ROS have an influence in vascular regulation and health. Indeed, the authors tested mitochondrial complexes I and III and Nox inhibitors and observed that only the mitochondrial inhibitors were able to exert effects in the regulation of flow-induced dilation. Besides the above evidence more studies are needed to explore the role of mitochondrial ROS in cerebral vasculature during disease progression, in contrast to the extensive literature concerning systemic vessels.

NADPH Oxidases

The Nox family is also broadly studied due to its main catalytic function of ROS production by transference of an electron to molecular oxygen. The Nox family is composed by different isoforms: Nox1 to 5, Duox1 and Duox2 with a broad expression in different organs and tissues and with different cellular locations at vascular walls. Except for Nox-5 and DUOX-1 and -2, Nox are phagocytic oxidases, whose main task is to generate ROS to kill foreign pathogens at homeostasis. Of note, the major source of endothelial cells ROS comes from NOX-1, -2, -4, and -5. Different Nox isoforms seem to produce different forms of ROS; Nox1 and 2 mainly produce O2•-; Nox4 mainly produces H2O2 and Nox5 seems to produce both O2•- and H2O2. Under physiological conditions, Nox-derived ROS seem to exert an important role in the regulation of vasodilatation. Although it is considered that under physiological conditions Nox activity is constitutively low, when its function increases with the consequent increase in ROS production, it can trigger ROS production by other sources. Indeed, it has been described that Nox-derived ROS play a major role in coordinating some physiological processes such as innate immunity, modulation of redox-dependent signaling cascades, and can act as cofactors in the production of hormones. Furthermore, it is described that H2O2 produced by Nox family can exert an endothelium-derived hyperpolarizing role causing vasodilatation and reducing blood pressure in mice. The Nox activity depends on the stimuli, such as cytokines, growth factors, hyperlipidemia, and high glucose. Additionally, Nox family is known for its role as oxygen sensors, modulating the different responses to hypoxia through hypoxia-inducible factor 1 alpha (HIF-1α) mRNA induction and HIF-1α stabilization, a process that is responsible for alterations in gene expression due to the oxidation of target proteins.

However, the overproduction of ROS by Nox family plays a major role in disruption of vascular homeostasis, which can underlie the development of neurodegenerative diseases. Of notice, so far only Nox2 and Nox4 were associated with endothelium dysfunction probably due to their major role as vascular ROS producers, in comparison to the other Nox isoforms.

Compelling evidence shows that Nox-derived oxidative stress causes many of the deleterious effects of angiotensin II on the cerebral vasculature. It was observed that angiotensin II acutely and chronically, increases O2•- production by Nox in rodent cerebral vessels. Also, functional alterations on rodents’ cerebral arterioles following angiotensin II treatment are prevented by co-treatment with the ROS scavenger MnTBAP and the Nox2 peptide inhibitor gp91ds-tat. It was also reported that angiotensin II can also activate and increase O2•- production in cerebral vessels by activating Nox1.

Interestingly, although not extensively studied, the Nox family activation and expression seems to be seasonal, a fact that could be correlated with seasonal alterations in oxidative stress and endothelium dysfunction observed in humans and rats unveiling a new strategic pathway to future studies of clinical relevance.

Aging and Neurodegenerative Disorders: When Things Start to Fail

The aging process causes several alterations in brain blood vessels such as decreased elasticity, increased cerebrovascular remodeling and calcification, gradual cerebrovascular wall stiffness, low-grade and widespread inflammation and oxidative stress, factors that increase the risk for cerebrovascular diseases. So far, there is no agreement of how aging process occurs although several theories can be found in the literature. One of the most accepted theory for aging was first proposed by and is known as “free radical theory of aging,” which postulates that ROS levels increase with age, being responsible for deoxyribonucleic acid (DNA), proteins and lipids oxidative damage.

Recent findings demonstrated the existence of BBB permeability alterations during normal aging in human hippocampus using advanced dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI). It is also known that aging increases BBB susceptibility to different challenges and its permeability is less controlled allowing the entrance of neurotoxic substances, which affect brain homeostasis. In fact, BBB dysfunction is more pronounced under pathological conditions, including in mild cognitive impairment (MCI) individuals, supporting the idea that vascular alterations are early events in cognitive deficits (Figure 2). Using a multiphoton microscope, observed increased levels of O2•- in the cerebral vessels of aged PS1/APP transgenic mice, a model of AD. Also, electron and confocal microscopy studies revealed that in F344 rats aortas, the expression of the mitochondrial biogenesis factors, such as mitochondrial transcription factor A and peroxisome proliferator-activated receptor-γ coactivator-1-alpha (PGC-1α), decreases with aging. Moreover, an increase in mitochondrial H2O2 production was observed in aged arterial rat vessels leading to an activation of nuclear factor-κB (NF-κB) and induction of inflammatory phenotypic changes in aged vasculature. Furthermore, an age-dependent decline in mitochondrial complexes I, III, and IV subunits expression was observed in rat aortas, although the authors did not specify if all the subunits of the three complexes were evaluated or not. Also, were able to show an age-dependent increase in mitochondrial ROS production and mitochondrial DNA lesions causing aorta vascular dysfunction in two different mice models, the ALDH-2–/– and MnSOD–/– models, which are deficient in aldehyde dehydrogenase-2 (ALDH-2) and manganese superoxide dismutase (MnSOD), respectively. Furthermore, the in vitro use of mitochondrial complex I inhibitor rotenone, after angiotensin II-induced O2•- production, showed significant improvements in endothelial dysfunction and tolerance in human aortic endothelial cells. Furthermore, the use of preconditioning strategies as a therapeutic intervention is emerging and under extensive scrutiny. Indeed, studies from our laboratory were able to show that treating rat brain endothelial cells with non-lethal cyanide concentrations, which lead to increased mitochondrial ROS production, was able to confer protection against a posterior high glucose-mediated damage, preventing apoptotic cell death. Importantly, were able to prove that in the absence of mitochondrial DNA, using mitochondrial-depleted DNA human teratocarcinoma NT2 cells, this effect was abrogated, emphasizing mitochondrial role in endothelium protection by preconditioning. Moreover, the use of mitochondrial-targeted antioxidants such as MitoTempo, showed promising results in counteracting age-related and microgravity-induced and hyperglycemia-induced endothelial dysfunction. Indeed, Mitotempo was able to protect endothelial primary cultures of diabetic mouse model (db/db) and rat cerebral arteries against amyloid β (Aβ) toxicity and lead to improvements in spatial working memory and motor skill learning in young 5xFAD mouse models of AD. Moreover, it was also able to recover mitochondrial dysfunction observed in rat cerebral arteries of animals exposed to microgravity conditions through reduction of mitochondrial ROS levels, increased mitochondrial potential and improvement in mitochondrial respiratory chain function.

Mitochondrial-derived oxidative stress can also activate vascular inflammation in aged carotid arteries and vessels leading to atherosclerosis through activation of endothelial NF-κB, which is responsible for the upregulation of adhesion molecules and increased monocyte adhesiveness in aged aortic arteries. Moreover, changes in Nox activity and/or expression is widely described in aged brain vessels. Nevertheless, the mechanistic role of Nox in the aging process remains obscure.

Data from the literature also show that in cultured aged cerebromicrovascular endothelial cells (CMVECs) the mRNA expression levels of Nox2 and 4 subunits were upregulated compared with young CMVECs, a phenomenon similar to that observed in the myocardium, leading to increased levels of oxidative stress. Although further studies must be performed in order to corroborate this hypothesis, it seems that, similarly to the myocardium, in CMVECs the increased expression of Nox 2 and 4 causes oxidative stress, which activates the renin–angiotensin–aldosterone system (RAAS). This activation can occur through a ROS-induced increase in angiotensinogen (AGT), a 60-kDa α2-globulin glycoprotein that constitutes the precursor of RAAS; stimulation of renin, the enzyme responsible for the initiation of the RAAS pathway; and release or regulation of angiotensin converting enzyme (ACE) activity, crucial for the formation of angiotensin II, the major effector of RAAS. Furthermore, since Nox 4 is usually localized in mitochondria, its increased expression can also contribute to increased levels of mitochondrial ROS potentiating the aging process as well as age-related diseases. The use of Nox inhibitors showed promising results in reducing oxidative stress levels and in improving endothelial function in several disease models. Also the use of resveratrol seems to be effective in restoring cerebromicrovascular endothelial function through a downregulation of Nox-derived ROS production in aged mice.

Despite the extensive literature stating that age-associated oxidative stress can lead to cerebrovascular dysfunction and cognitive decline, there is a significant gap in our knowledge regarding the exact mechanisms underlying these defects.

Cerebrovascular Oxidative Stress and Neurodegenerative Events: the Case of Alzheimer’s Disease

Although the previous alterations seem to be common features in physiological aging of vessels, somewhere over the way those defects can become more pronounced triggering neurodegenerative events. Indeed, recent reports suggest a major role for the NVU in the initiation of neurodegeneration. In fact, NVU dysfunction leads to an increased BBB permeability with the subsequent entry of neurotoxic molecules into the brain disturbing its homeostasis. A decrease in the removal of neurotoxic substances from the brain, and a deficient nutrient delivery system eventually culminate in neuronal loss and synaptic dysfunction. Thus, a decline in cerebrovascular function in age-associated diseases, such as AD, is easily understandable. Indeed, it is estimated that about 60–90% of AD patients also present cerebrovascular alterations including cerebral amyloid angiopathy (CAA), microinfarcts and ischemic lesions and microvascular degeneration.

It has been recently reported the existence of BBB and vascular alterations in several diseases such as Parkinson’s disease (PD), Huntington’s disease and cerebral small vessel disease although there is a gap concerning the mechanisms underlying those alterations and the role of vascular oxidative stress in these pathologies.

Concerning AD, the most common form of dementia in the elderly, more information exists about the vascular alterations that occur in this disease. Several clinical and basic evidence points to the existence of a major contribution of both large artery and small vessel disease in the pathogenesis of AD. Having this into account, the two-hit vascular hypothesis of AD emerged, postulating that cerebrovascular damage is an initial insult that is self-sufficient to initiate neuronal injury and neurodegeneration, but can also promote accumulation of Aβ peptide, a neurotoxic peptide, in the brain. Thus, events that compromise vascular health can initiate a cascade of deleterious events that culminate in AD development. In fact, previous studies from our laboratory demonstrated that some risk factors for AD, such as hyperglycemia, increase the susceptibility of brain endothelial cells to Aβ peptide, a phenomenon related to ROS overproduction. Moreover, several genetic [apolipoprotein E4 (APOE4), phosphatidylinositol-binding clathrin assembly protein (PICALM), clusterin, presenilin 1, amyloid precursor protein (APP), mesenchyme homeobox gene 2 (MEOX2)] and non-genetic (hypertension, metabolic syndrome, hypercholesterolemia, atherosclerosis, alcohol and substance abuse, among others) risk factors for AD seem to be linked with alterations in vascular function supporting the idea that vascular alterations play a major role in AD pathology.

Recent studies in wild type mice showed that, even under normal conditions, there is a different regional susceptibility of the cerebrovasculature to oxidative stress. Vessels from cortex and hippocampus, the two main areas compromised in AD, contain significantly higher levels of intracellular O2•- and increased protein levels of both Nox 2 and 4. Other studies revealed significant changes in blood vessels morphology, decreased vascular density and increased vessels tortuosity in AD brains. Moreover, the use of recent technologies such as arterial spin labeling magnetic resonance imaging (MRI), functional blood-oxygen-level-dependent (BOLD)-MRI, fluorodeoxyglucose-positron emission tomography (FDG-PET), and single-photon emission computerized tomography (SPECT), showed decreased levels of CBF in early phases of human AD progression. Recently, showed that reduced CBF changes found in triple transgenic for AD (3xTg-AD) mice preceded memory dysfunction thus suggesting that cerebrovascular dysfunction could be the primary cause of neurovascular uncoupling in AD. Those observations are supported by MRI, transcranial doppler and SPECT studies revealing different patterns of decreased CBF coincident with the brain regions where neuropathological alterations are more relevant in AD. Those alterations seem to be closely related with the levels of oxidative stress in the cerebrovasculature. Studies from our laboratory showed that 3xTg-AD mice present an increased BBB permeability, in cortex and hippocampus, these alterations being correlated with decreased aconitase activity, an enzyme whose activity is inhibited by O2•-. The increased levels of ROS appeared to be the result of impaired activity of mitochondrial enzymatic complexes I–III (Figure 2). Moreover, and similarly to our observations in mitochondria isolated from whole brain of 3xTg-AD mice, Golgi silver impregnation studies using multiple samples from the hippocampus and cortices of AD patients showed that brain endothelial cells present enlarged mitochondria, disruption of the mitochondrial cristae and reduced abundance.

An interesting fact is that even though mitochondrial morphology is very similar in male and female rodent cerebral arteries, major differences can be observed concerning mitochondrial protein mass, respiration, and function, which is in accordance with sex/gender differences observed in several brain-related studies including the susceptibility to develop AD.

Mitochondrial ROS overproduction also increases Aβ deposition in vessels walls, which is a common feature in many cases of AD (Figure 2). Indeed, 34–35% of human AD cases present CAA, predominantly in the occipital lobe. Aβ deposition in vessels walls seems to initiate a vicious cycle, Aβ increases ROS levels, which in turn potentiate Aβ deposition (Figure 2). There is also evidence showing that Aβ can induce Nox activation and ROS production, which are responsible for the activation of multiple mechanisms involved in vascular dysfunction and decreased levels of tight junction proteins mRNA. However, Nox driven ROS production does not seem to affect Aβ production in Tg2576 mice, a mouse model of AD, lacking the key Nox 2 subunit.

Endothelial ROS overproduction upregulates the endothelial production and release of endothelin-1, a well know vasoconstrictor that appears to be increased in AD. Likewise, ROS overproduction seems to be responsible for reduced •NO bioavailability mainly by its fast reaction with O2•- generating ONOO- and for a decreased activity of potassium channels, two major factors required for endothelial-mediated dilations in brain vasculature. Moreover, Aβ-induced nitrosative stress in endothelial cells is also responsible for DNA damage, resulting in poly (ADP-ribose) polymerase (PARP) activation, ultimately leading to a large increase in intracellular Ca2+ through transient receptor potential melastatin-2 channels activation (Figure 2).

Reactive oxygen species overproduction also interferes with HIF-1α reducing its expression and activity which will restrain the stimulus to promote angiogenesis and new vessels formation leading to a vicious cycle of impaired capillary perfusion, hypoxia and oxidative stress.

Final Remarks

Recognizing vascular ROS production as one of the main causes of BBB dysfunction in aging and dementia, particularly in AD, raises the prospect that pharmacotherapy targeting the major ROS producers, namely mitochondria and/or Nox, might open a new venue to stop or, at least, slow dementia progression. Indeed, relying on the overwhelming evidence that mitochondrial dysfunction could be in the genesis of neurovascular dysfunction, several molecules with potential therapeutic effects were designed to target ROS, boost mitochondrial function and decrease free radical production and oxidative damage in an attempt to improve neurovascular health. Some of those molecules ameliorated the cognitive performance of mouse models of cerebrovascular disease. It was observed that the steroid hormone 17β-estradiol (estrogen) modulates the expression of several transcriptional regulators causing a decrease in PGC-1α, and an increase in PGC-1β, PGC-1-related coactivator (PRC), nuclear respiratory factor 1 (NRF-1) and mitochondrial transcription factor A (TFAM), which protect cerebral blood vessels (Table 1). These protective effects were due to increased mitochondrial biogenesis and antioxidant enzymes. However, the use of antioxidant therapy in cerebrovascular disease still needs validation. Indeed, several promising approaches failed in clinical trials, opening an intense debate about the reasons for the failure of those molecules in humans. Merely as an example, the use of tempol showed promising results in improving vasodilator responses of cerebral arterioles in aged APP transgenic mice with CAA but so far there is no evidence of its efficacy in clinical trials. Furthermore, two major concerns arise from the use of antioxidants as therapeutic approaches: (1) physiological ROS concentrations are important in normal cell functioning and the use of antioxidants may interfere with ROS signaling and (2) the concentrations of antioxidants revealed to be suboptimal doses in certain situations. Indeed, it is known now that supra-physiological concentrations are required to compete with the constant reaction that usually occurs between O2•- and •NO. Large part of the studies failed to prove that antioxidants reach the vasculature at appropriate/therapeutic concentrations.

To overcome the failure of the traditional antioxidants, researchers are developing new specific-targeted antioxidants. However, evidence about the specific-target antioxidants effects in endothelial cells is scarce. Moreover, mitochondria-targeted antioxidants decrease the dose required and limit toxic side effects rendering them a promising therapeutic approach. It was observed that MitoTempo, a mitochondria-targeted antioxidant, was able to counteract Aβ-induced damage under hyperglycemic conditions in rat and mouse primary cultures of endothelial cells. Additionally, it was shown that MitoTempo was able to improve mitochondrial function and coronary collateral growth after ischemia/reperfusion in Zucker fatty rats (Table 1). Recent studies also showed that MitoTempo was able to decrease vascular O2•- and increase vascular •NO production improving endothelial-dependent relaxation in angiotensin II-induced hypertensive C57Bl/6 mice. It was also observed that MitoTempo improves endothelial function and reduces mitochondrial O2•- levels in subcutaneous arterioles isolated from type 2 diabetic patients (Table 1). Moreover, MitoQ, another mitochondria-targeted antioxidant was able to reduce oxidative stress, without causing adverse effects, on wild-type mice and animal models of neurodegenerative diseases such as AD and PD. MitoQ was able to improve age-related arterial endothelial dysfunction in C57BL/6 mice (Table 1). Furthermore, MitoQ has been shown to prevent cocaine-induced cardiac dysfunction in Wistar rats. However, the use of mitochondrial-directed drugs should take in account two major limitations: first, the lack of organ-specificity, leading to a greater accumulation in mitochondria-rich tissues; and second the typically used chemicals tend to accumulate in the matrix and the matrix-facing surface of the inner mitochondrial membrane, over other important mitochondrial compartments. The majority of mitochondria-targeted compounds were already able to identify and get ahead of these limiting factors in human clinical trials, defining the amount of the compound that can be administered safely. For example, MitoQ, was already developed as a pharmaceutical by Antipodean Pharmaceuticals Inc. and clinical trials are running, namely in type 2 diabetic patients, where MitoQ treatment was able to decrease ROS levels and significantly reduced the adhesion of leukocytes to endothelial cells in type 2 diabetic individuals.

Likewise, approaches designed to target Nox-derived ROS overproduction are also under intense scrutiny. Indeed, the genetic deletion or inhibition of Nox2 seems effective in improving cerebral vessels functioning in aged APP mice. Apocynin and diphenyleniodonium are widely used to ameliorate Nox-related cerebrovascular dysfunction, however, both compounds present non-specific effects and cannot be used in the clinic (Table 1). In this line, several attempts are being made to synthesize new Nox inhibitors including fulvene-5, triphenylmethane derivatives, grindelic acid, and ML171 (Table 1). However, results are scarce and further studies are needed to demonstrate that those compounds are potential therapeutics for the treatment of neurodegenerative conditions characterized by oxidative stress-associated vascular alterations.

In sum, despite the existing information about the role of cerebrovascular oxidative stress in neurodegenerative conditions, a long way is still ahead to clarify the mechanisms of age-associated vascular damage and subsequent neurodegenerative conditions. New information is crucial for the design of more effective therapeutic strategies.

Author Contributions

CC performed literature search and wrote the paper. PM provided a critical revision of the paper.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The handling Editor declared a shared affiliation, though no other collaboration, with the authors.

References 180

  1. 1.

    Agarwal R. Shukla G. S. (1999 ). Potential role of cerebral glutathione in the maintenance of blood-brain barrier integrity in rat. Neurochem. Res. 24 1507–1514.

    Not in our library10.1023/a:1021191729865

  2. 2.
    Direct Activation of RhoA by Reactive Oxygen Species Requires a Redox-Sensitive Motif · 2009
    No notice
  3. 3.

    Al-Bachari S. Vidyasagar R. Emsley H. C. Parkes L. M. (2017 ). Structural and physiological neurovascular changes in idiopathic Parkinson’s disease and its clinical phenotypes. J. Cereb. Blood Flow Metab. 37 3409–3421.

    Not in our library10.1177/0271678x16688919

  4. 4.
    Reactive Oxygen Species in Health and Disease · 2012
    No notice
  5. 5.

    Allen C. L. Bayraktutan U. (2009 ). Oxidative stress and its role in the pathogenesis of ischaemic stroke. Int. J. Stroke 4 461–470.

    Not in our library10.1111/j.1747-4949.2009.00387.x

  6. 6.

    Alyautdin R. Khalin I. Nafeeza M. I. Haron M. H. Kuznetsov D. (2014 ). Nanoscale drug delivery systems and the blood-brain barrier. Int. J. Nanomedicine 9 795–811.

    Not in our library10.2147/ijn.s52236

  7. 7.

    Armulik A. Genove G. Mae M. Nisancioglu M. H. Wallgard E. Niaudet C. (2010 ). Pericytes regulate the blood-brain barrier. Nature 468 557–561.

    Not in our library10.1038/nature09522

  8. 8.

    Austin S. A. Santhanam A. V. d’Uscio L. V. Katusic Z. S. (2015 ). Regional heterogeneity of cerebral microvessels and brain susceptibility to oxidative stress. PLoS One 10:e0144062.

    Not in our library10.1371/journal.pone.0144062

  9. 9.

    Baloyannis S. J. Baloyannis I. S. (2012 ). The vascular factor in Alzheimer’s disease: a study in Golgi technique and electron microscopy. J. Neurol. Sci. 322 117–121.

    Not in our library10.1016/j.jns.2012.07.010

  10. 10.

    Bell R. D. Zlokovic B. V. (2009 ). Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer’s disease. Acta Neuropathol. 118 103–113.

    Not in our library10.1007/s00401-009-0522-3

  11. 11.

    Bhandarkar S. S. Jaconi M. Fried L. E. Bonner M. Y. Lefkove B. Govindarajan B. (2009 ). Fulvene-5 potently inhibits NADPH oxidase 4 and blocks the growth of endothelial tumors in mice. J. Clin. Invest. 119 2359–2365.

    Not in our library10.1172/jci33877

  12. 12.

    Brandes R. P. Viedt C. Nguyen K. Beer S. Kreuzer J. Busse R. (2001 ). Thrombin-induced MCP-1 expression involves activation of the p22phox-containing NADPH oxidase in human vascular smooth muscle cells. Thromb. Haemost. 85 1104–1110.

    Not in our library10.1055/s-0037-1615970

  13. 13.

    Brown G. C. Borutaite V. (2001 ). Nitric oxide, mitochondria, and cell death. IUBMB Life 52 189–195.

    Not in our library10.1080/15216540152845993

  14. 14.

    Busija D. W. Katakam P. V. (2014 ). Mitochondrial mechanisms in cerebral vascular control: shared signaling pathways with preconditioning. J. Vasc. Res. 51 175–189.

    Not in our library10.1159/000360765

  15. 15.

    Busija D. W. Rutkai I. Dutta S. Katakam P. V. (2016 ). Role of mitochondria in cerebral vascular function: energy production, cellular protection, and regulation of vascular tone. Compr. Physiol. 6 1529–1548.

    Not in our library10.1002/cphy.c150051

  16. 16.

    Cadenas E. Davies K. J. (2000 ). Mitochondrial free radical generation, oxidative stress, and aging. Free Radic. Biol. Med. 29 222–230.

    Not in our library10.1016/s0891-5849(00)00317-8

  17. 17.

    Camici G. G. Savarese G. Akhmedov A. Luscher T. F. (2015 ). Molecular mechanism of endothelial and vascular aging: implications for cardiovascular disease. Eur. Heart J. 36 3392–3403.

    Not in our library10.1093/eurheartj/ehv587

  18. 18.

    Campos-Pena V. Toral-Rios D. Becerril-Perez F. Sanchez-Torres C. Delgado-Namorado Y. Torres-Ossorio E. (2017 ). Metabolic syndrome as a risk factor for Alzheimer’s disease: is abeta a crucial factor in both pathologies? Antioxid. Redox Signal. 26 542–560.

    Not in our library10.1089/ars.2016.6768

  19. 19.

    Candeias E. Duarte A. I. Sebastiao I. Fernandes M. A. Placido A. I. Carvalho C. (2017 ). Middle-aged diabetic females and males present distinct susceptibility to Alzheimer disease-like pathology. Mol. Neurobiol. 54 6471–6489.

    Not in our library10.1007/s12035-016-0155-1

  20. 20.

    Caplan L. R. Biller J. Leary M. C. Lo E. H. Thomas A. J. Yenari M. (2017 ). Primer on Cerebrovascular Diseases. Amsterdam: Elsevier Science.

    Not in our library

  21. 21.

    Carrano A. Hoozemans J. J. van der Vies S. M. Rozemuller A. J. van Horssen J. de Vries H. E. (2011 ). Amyloid Beta induces oxidative stress-mediated blood-brain barrier changes in capillary amyloid angiopathy. Antioxid. Redox Signal. 15 1167–1178.

    Not in our library10.1089/ars.2011.3895

  22. 22.

    Carvalho C. Cardoso S. Correia S. C. Santos R. X. Santos M. S. Baldeiras I. (2012 ). Metabolic alterations induced by sucrose intake and Alzheimer’s disease promote similar brain mitochondrial abnormalities. Diabetes 61 1234–1242.

    Not in our library10.2337/db11-1186

  23. 23.

    Carvalho C. Correia S. Santos R. Cardoso S. Santos M. Moreira P. (2010 ). “Diabetes, mitochondria and brain endothelium dysfunction: a dangerous triad for neurodegeneration?,” in Mitochondria: Structure, Functions and Dysfunctions, ed. Svensson O. (Hauppauge, NY: Nova Science Publishers, Inc.), 561–577.

    Not in our library

  24. 24.

    Carvalho C. Correia S. C. Cardoso S. Placido A. I. Candeias E. Duarte A. I. (2015 ). The role of mitochondrial disturbances in Alzheimer, Parkinson and Huntington diseases. Expert Rev. Neurother. 15 867–884.

    Not in our library10.1586/14737175.2015.1058160

  25. 25.

    Carvalho C. Katz P. S. Dutta S. Katakam P. V. Moreira P. I. Busija D. W. (2014 ). Increased susceptibility to amyloid-beta toxicity in rat brain microvascular endothelial cells under hyperglycemic conditions. J. Alzheimers Dis. 38 75–83.

    Not in our library10.3233/jad-130464

  26. 26.

    Carvalho C. Machado N. Mota P. Correia S. Cardoso S. Santos R. (2013 ). Type 2 diabetic and Alzheimer’s disease mice present similar behavioral, cognitive and vascular anomalies. J. Alzheimer Dis. 35 623–635.

    Not in our library10.3233/jad-130005

  27. 27.

    Chan D. C. (2006 ). Mitochondria: dynamic organelles in disease, aging, and development. Cell 125 1241–1252.

    Not in our library10.1016/j.cell.2006.06.010

  28. 28.

    Chen Q. Wang Q. Zhu J. Xiao Q. Zhang L. (2017 ). Reactive oxygen species: key regulators in vascular health and diseases. Br. J. Pharmacol. 175 1279–1292.

    Not in our library10.1111/bph.13828

  29. 29.

    Christov-Moore L. Simpson E. A. Coude G. Grigaityte K. Iacoboni M. Ferrari P. F. (2014 ). Empathy: gender effects in brain and behavior. Neurosci. Biobehav. Rev. 46(Pt 4), 604–627.

    Not in our library10.1016/j.neubiorev.2014.09.001

  30. 30.

    Correia S. C. Carvalho C. Cardoso S. Santos R. X. Santos M. S. Oliveira C. R. (2010 ). Mitochondrial preconditioning: a potential neuroprotective strategy. Front. Aging Neurosci. 2:138

    Not in our library10.3389/fnagi.2010.00138

  31. 31.

    Correia S. C. Santos R. X. Cardoso S. M. Santos M. S. Oliveira C. R. Moreira P. I. (2012 ). Cyanide preconditioning protects brain endothelial and NT2 neuron-like cells against glucotoxicity: role of mitochondrial reactive oxygen species and HIF-1alpha. Neurobiol. Dis. 45 206–218.

    Not in our library10.1016/j.nbd.2011.08.005

  32. 32.

    Csiszar A. Labinskyy N. Orosz Z. Xiangmin Z. Buffenstein R. Ungvari Z. (2007 ). Vascular aging in the longest-living rodent, the naked mole rat. Am. J. Physiol. Heart Circ. Physiol. 293 H919–H927.

    Not in our library10.1152/ajpheart.01287.2006

  33. 33.

    Culic O. Gruwel M. L. Schrader J. (1997 ). Energy turnover of vascular endothelial cells. Am. J. Physiol. 273(1 Pt 1), C205–C213.

    Not in our library10.1152/ajpcell.1997.273.1.c205

  34. 34.

    Daneman R. Prat A. (2015 ). The blood-brain barrier. Cold Spring Harb. Perspect. Biol. 7:a020412.

    Not in our library10.1101/cshperspect.a020412

  35. 35.

    de Almeida A. Ribeiro T. P. de Medeiros I. A. (2017 ). Aging: molecular pathways and implications on the cardiovascular system. Oxid. Med. Cell. Longev. 2017:7941563.

    Not in our library10.1155/2017/7941563

  36. 36.

    De Keulenaer G. W. Alexander R. W. Ushio-Fukai M. Ishizaka N. Griendling K. K. (1998 ). Tumour necrosis factor alpha activates a p22phox-based NADH oxidase in vascular smooth muscle. Biochem. J. 329(Pt 3), 653–657.

    Not in our library10.1042/bj3290653

  37. 37.

    De Silva T. M. Faraci F. M. (2016 ). Microvascular dysfunction and cognitive impairment. Cell. Mol. Neurobiol. 36 241–258.

    Not in our library10.1007/s10571-015-0308-1

  38. 38.

    De Silva T. M. Miller A. A. (2016 ). Cerebral small vessel disease: targeting oxidative stress as a novel therapeutic strategy? Front. Pharmacol. 7:61.

    Not in our library10.3389/fphar.2016.00061

  39. 39.

    De Strooper B. Karran E. (2016 ). The cellular phase of Alzheimer’s disease. Cell 164 603–615.

    Not in our library10.1016/j.cell.2015.12.056

  40. 40.

    Didion S. P. Faraci F. M. (2002 ). Effects of NADH and NADPH on superoxide levels and cerebral vascular tone. Am. J. Physiol. Heart Circ. Physiol. 282 H688–H695.

    Not in our library10.1152/ajpheart.00576.2001

  41. 41.

    Dikalov S. I. Nazarewicz R. R. Bikineyeva A. Hilenski L. Lassegue B. Griendling K. K. (2014 ). Nox2-induced production of mitochondrial superoxide in angiotensin II-mediated endothelial oxidative stress and hypertension. Antioxid. Redox Signal. 20 281–294.

    Not in our library10.1089/ars.2012.4918

  42. 42.

    Dikalov S. I. Dikalova A. E. Bikineyeva A. T. Schmidt H. H. Harrison D. G. Griendling K. K. (2008 ). Distinct roles of Nox1 and Nox4 in basal and angiotensin II-stimulated superoxide and hydrogen peroxide production. Free Radic. Biol. Med. 45 1340–1351.

    Not in our library10.1016/j.freeradbiomed.2008.08.013

  43. 43.

    Ding X. Zhang M. Gu R. Xu G. Wu H. (2017 ). Activated microglia induce the production of reactive oxygen species and promote apoptosis of co-cultured retinal microvascular pericytes. Graefes Arch. Clin. Exp. Ophthalmol. 255 777–788.

    Not in our library10.1007/s00417-016-3578-5

  44. 44.

    Dromparis P. Michelakis E. D. (2012 ). Mitochondria in vascular health and disease. Annu. Rev. Physiol. 75 95–126.

    Not in our library10.1146/annurev-physiol-030212-183804

  45. 45.

    Drummond G. R. Selemidis S. Griendling K. K. Sobey C. G. (2011 ). Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets. Nat. Rev. Drug Discov. 10 453–471.

    Not in our library10.1038/nrd3403

  46. 46.

    Drummond G. R. Sobey C. G. (2014 ). Endothelial NADPH oxidases: which NOX to target in vascular disease? Trends Endocrinol. Metab. 25 452–463.

    Not in our library10.1016/j.tem.2014.06.012

  47. 47.
    Triggers and Effectors of Oxidative Stress at Blood-Brain Barrier Level: Relevance for Brain Ageing and Neurodegeneration · 2013
    No notice
  48. 48.

    Erdos B. Snipes J. A. Miller A. W. Busija D. W. (2004 ). Cerebrovascular dysfunction in Zucker obese rats is mediated by oxidative stress and protein kinase C. Diabetes 53 1352–1359.

    Not in our library10.2337/diabetes.53.5.1352

  49. 49.

    Escribano-Lopez I. Diaz-Morales N. Rovira-Llopis S. de Maranon A. M. Orden S. Alvarez A. (2016 ). The mitochondria-targeted antioxidant MitoQ modulates oxidative stress, inflammation and leukocyte-endothelium interactions in leukocytes isolated from type 2 diabetic patients. Redox Biol. 10 200–205.

    Not in our library10.1016/j.redox.2016.10.017

  50. 50.

    Faraci F. M. (2017 ). Disease highlights the cellular diversity of neurovascular units: sign in stranger. Circ. Res. 121 203–205.

    Not in our library10.1161/circresaha.117.311386

  51. 51.

    Faraci F. M. Sobey C. G. (1998 ). Role of potassium channels in regulation of cerebral vascular tone. J. Cereb. Blood Flow Metab. 18 1047–1063.

    Not in our library10.1097/00004647-199810000-00001

  52. 52.

    Faraco G. Moraga A. Moore J. Anrather J. Pickel V. M. Iadecola C. (2013 ). Circulating endothelin-1 alters critical mechanisms regulating cerebral microcirculation. Hypertension 62 759–766.

    Not in our library10.1161/hypertensionaha.113.01761

  53. 53.

    Faraco G. Sugiyama Y. Lane D. Garcia-Bonilla L. Chang H. Santisteban M. M. (2016 ). Perivascular macrophages mediate the neurovascular and cognitive dysfunction associated with hypertension. J. Clin. Invest. 126 4674–4689.

    Not in our library10.1172/jci86950

  54. 54.

    Freeman L. R. Keller J. N. (2012 ). Oxidative stress and cerebral endothelial cells: regulation of the blood-brain-barrier and antioxidant based interventions. Biochim. Biophys. Acta 1822 822–829.

    Not in our library10.1016/j.bbadis.2011.12.009

  55. 55.

    Gallart-Palau X. Lee B. S. Adav S. S. Qian J. Serra A. Park J. E. (2016 ). Gender differences in white matter pathology and mitochondrial dysfunction in Alzheimer’s disease with cerebrovascular disease. Mol. Brain 9:27.

    Not in our library10.1186/s13041-016-0205-7

  56. 56.

    Ghosh A. Chandran K. Kalivendi S. V. Joseph J. Antholine W. E. Hillard C. J. (2010 ). Neuroprotection by a mitochondria-targeted drug in a Parkinson’s disease model. Free Radic. Biol. Med. 49 1674–1684.

    Not in our library10.1016/j.freeradbiomed.2010.08.028

  57. 57.

    Gianni D. Taulet N. Zhang H. DerMardirossian C. Kister J. Martinez L. (2010 ). A novel and specific NADPH oxidase-1 (Nox1) small-molecule inhibitor blocks the formation of functional invadopodia in human colon cancer cells. ACS Chem. Biol. 5 981–993.

    Not in our library10.1021/cb100219n

  58. 58.

    Giordano G. Tait L. Furlong C. E. Cole T. B. Kavanagh T. J. Costa L. G. (2013 ). Gender differences in brain susceptibility to oxidative stress are mediated by levels of paraoxonase-2 expression. Free Radic. Biol. Med. 58 98–108.

    Not in our library10.1016/j.freeradbiomed.2013.01.019

  59. 59.

    Gioscia-Ryan R. A. LaRocca T. J. Sindler A. L. Zigler M. C. Murphy M. P. Seals D. R. (2014 ). Mitochondria-targeted antioxidant (MitoQ) ameliorates age-related arterial endothelial dysfunction in mice. J. Physiol. 592 2549–2561.

    Not in our library10.1113/jphysiol.2013.268680

  60. 60.

    Girouard H. Iadecola C. (2006 ). Neurovascular coupling in the normal brain and in hypertension, stroke, and Alzheimer disease. J. Appl. Physiol. 100 328–335.

    Not in our library10.1152/japplphysiol.00966.2005

  61. 61.

    Girouard H. Park L. Anrather J. Zhou P. Iadecola C. (2006 ). Angiotensin II attenuates endothelium-dependent responses in the cerebral microcirculation through nox-2-derived radicals. Arterioscler. Thromb. Vasc. Biol. 26 826–832.

    Not in our library10.1161/01.atv.0000205849.22807.6e

  62. 62.

    Girouard H. Park L. Anrather J. Zhou P. Iadecola C. (2007 ). Cerebrovascular nitrosative stress mediates neurovascular and endothelial dysfunction induced by angiotensin II. Arterioscler. Thromb. Vasc. Biol. 27 303–309.

    Not in our library10.1161/01.atv.0000253885.41509.25

  63. 63.

    Goetz M. E. Luch A. (2008 ). Reactive species: a cell damaging rout assisting to chemical carcinogens. Cancer Lett. 266 73–83.

    Not in our library10.1016/j.canlet.2008.02.035

  64. 64.

    Gordon G. R. Mulligan S. J. MacVicar B. A. (2007 ). Astrocyte control of the cerebrovasculature. Glia 55 1214–1221.

    Not in our library10.1002/glia.20543

  65. 65.

    Gorlach A. Diebold I. Schini-Kerth V. B. Berchner-Pfannschmidt U. Roth U. Brandes R. P. (2001 ). Thrombin activates the hypoxia-inducible factor-1 signaling pathway in vascular smooth muscle cells: role of the p22(phox)-containing NADPH oxidase. Circ. Res. 89 47–54.

    Not in our library10.1161/hh1301.092678

  66. 66.

    Grochowski C. Litak J. Kamieniak P. Maciejewski R. (2018 ). Oxidative stress in cerebral small vessel disease. Role of reactive species. Free Radic. Res. 52 1–13.

    Not in our library10.1080/10715762.2017.1402304

  67. 67.

    Halliwell B. (2001 ). Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment. Drugs Aging 18 685–716.

    Not in our library10.2165/00002512-200118090-00004

  68. 68.

    Hamel E. Nicolakakis N. Aboulkassim T. Ongali B. Tong X. K. (2008 ). Oxidative stress and cerebrovascular dysfunction in mouse models of Alzheimer’s disease. Exp. Physiol. 93 116–120.

    Not in our library10.1113/expphysiol.2007.038729

  69. 69.

    Hamel E. Royea J. Ongali B. Tong X. K. (2016 ). Neurovascular and cognitive failure in Alzheimer’s disease: benefits of cardiovascular therapy. Cell. Mol. Neurobiol. 36 219–232.

    Not in our library10.1007/s10571-015-0285-4

  70. 70.

    Han B. H. Zhou M. L. Johnson A. W. Singh I. Liao F. Vellimana A. K. (2015 ). Contribution of reactive oxygen species to cerebral amyloid angiopathy, vasomotor dysfunction, and microhemorrhage in aged Tg2576 mice. Proc. Natl. Acad. Sci. U.S.A. 112 E881–E890.

    Not in our library10.1073/pnas.1414930112

  71. 71.

    Harman D. (1956 ). Aging: a theory based on free radical and radiation chemistry. J. Gerontol. 11 298–300.

    Not in our library10.1093/geronj/11.3.298

  72. 72.

    Helmcke I. Heumuller S. Tikkanen R. Schroder K. Brandes R. P. (2009 ). Identification of structural elements in Nox1 and Nox4 controlling localization and activity. Antioxid. Redox Signal. 11 1279–1287.

    Not in our library10.1089/ars.2008.2383

  73. 73.

    Hopkins N. D. Stratton G. Tinken T. M. Ridgers N. D. Graves L. E. McWhannell N. (2011 ). Seasonal reduction in physical activity and flow-mediated dilation in children. Med. Sci. Sports Exerc. 43 232–238.

    Not in our library10.1249/mss.0b013e3181ebe90e

  74. 74.

    Hu W. T. Wang Z. Lee V. M. Trojanowski J. Q. Detre J. A. Grossman M. (2010 ). Distinct cerebral perfusion patterns in FTLD and AD. Neurology 75 881–888.

    Not in our library10.1212/wnl.0b013e3181f11e35

  75. 75.
    Morphological and Pathological Evolution of the Brain Microcirculation in Aging and Alzheimer’s Disease · 2012
    No notice
  76. 76.

    Iadecola C. (2013 ). The pathobiology of vascular dementia. Neuron 80 844–866.

    Not in our library10.1016/j.neuron.2013.10.008

  77. 77.

    Ingalhalikar M. Smith A. Parker D. Satterthwaite T. D. Elliott M. A. Ruparel K. (2014 ). Sex differences in the structural connectome of the human brain. Proc. Natl. Acad. Sci. U.S.A. 111 823–828.

    Not in our library10.1073/pnas.1316909110

  78. 78.

    Jackman K. A. Miller A. A. Drummond G. R. Sobey C. G. (2009 ). Importance of NOX1 for angiotensin II-induced cerebrovascular superoxide production and cortical infarct volume following ischemic stroke. Brain Res. 1286 215–220.

    Not in our library10.1016/j.brainres.2009.06.056

  79. 79.

    Jansen F. Yang X. Franklin B. S. Hoelscher M. Schmitz T. Bedorf J. (2013 ). High glucose condition increases NADPH oxidase activity in endothelial microparticles that promote vascular inflammation. Cardiovasc. Res. 98 94–106.

    Not in our library10.1093/cvr/cvt013

  80. 80.

    Jellinger K. A. Mitter-Ferstl E. (2003 ). The impact of cerebrovascular lesions in Alzheimer disease–a comparative autopsy study. J. Neurol. 250 1050–1055.

    Not in our library10.1007/s00415-003-0142-0

  81. 81.

    Kahles T. Luedike P. Endres M. Galla H. J. Steinmetz H. Busse R. (2007 ). NADPH oxidase plays a central role in blood-brain barrier damage in experimental stroke. Stroke 38 3000–3006.

    Not in our library10.1161/strokeaha.107.489765

  82. 82.

    Kemper M. F. Stirone C. Krause D. N. Duckles S. P. Procaccio V. (2014 ). Genomic and non-genomic regulation of PGC1 isoforms by estrogen to increase cerebral vascular mitochondrial biogenesis and reactive oxygen species protection. Eur. J. Pharmacol. 723 322–329.

    Not in our library10.1016/j.ejphar.2013.11.009

  83. 83.

    Kivipelto M. Laakso M. P. Tuomilehto J. Nissinen A. Soininen H. (2002 ). Hypertension and hypercholesterolaemia as risk factors for Alzheimer’s disease: potential for pharmacological intervention. CNS Drugs 16 435–444.

    Not in our library10.2165/00023210-200216070-00001

  84. 84.

    Kizhakekuttu T. J. Wang J. Dharmashankar K. Ying R. Gutterman D. D. Vita J. A. (2012 ). Adverse alterations in mitochondrial function contribute to type 2 diabetes mellitus-related endothelial dysfunction in humans. Arterioscler. Thromb. Vasc. Biol. 32 2531–2539.

    Not in our library10.1161/atvbaha.112.256024

  85. 85.

    Kling M. A. Trojanowski J. Q. Wolk D. A. Lee V. M. Arnold S. E. (2013 ). Vascular disease and dementias: paradigm shifts to drive research in new directions. Alzheimers Dement. 9 76–92.

    Not in our library10.1016/j.jalz.2012.02.007

  86. 86.

    Kluge M. A. Fetterman J. L. Vita J. A. (2013 ). Mitochondria and endothelial function. Circ. Res. 112 1171–1188.

    Not in our library10.1161/circresaha.111.300233

  87. 87.

    Konior A. Schramm A. Czesnikiewicz-Guzik M. Guzik T. J. (2014 ). NADPH oxidases in vascular pathology. Antioxid. Redox Signal. 20 2794–2814.

    Not in our library10.1089/ars.2013.5607

  88. 88.

    Kubíková T. Kochova P. Tomasek P. Witter K. Tonar Z. (2017 ). Numerical and length densities of microvessels in the human brain: correlation with preferential orientation of microvessels in the cerebral cortex, subcortical grey matter and white matter, pons and cerebellum. J. Chem. Neuroanat. 88 22–32.

    Not in our library10.1016/j.jchemneu.2017.11.005

  89. 89.

    Landmesser U. Dikalov S. Price S. R. McCann L. Fukai T. Holland S. M. (2003 ). Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J. Clin. Invest. 111 1201–1209.

    Not in our library10.1172/jci14172

  90. 90.

    Lee H. Pienaar I. S. (2014 ). Disruption of the blood-brain barrier in Parkinson’s disease: curse or route to a cure? Front. Biosci. 19 272–280.

    Not in our library10.2741/4206

  91. 91.

    Lee J. M. Shih A. Y. Murphy T. H. Johnson J. A. (2003 ). NF-E2-related factor-2 mediates neuroprotection against mitochondrial complex I inhibitors and increased concentrations of intracellular calcium in primary cortical neurons. J. Biol. Chem. 278 37948–37956.

    Not in our library10.1074/jbc.m305204200

  92. 92.

    Leitao-Rocha A. Guedes-Dias P. Pinho B. R. Oliveira J. M. (2015 ). Trends in mitochondrial therapeutics for neurological disease. Curr. Med. Chem. 22 2458–2467.

    Not in our library10.2174/0929867322666150209160317

  93. 93.

    Li J. Li W. Su J. Liu W. Altura B. T. Altura B. M. (2003 ). Hydrogen peroxide induces apoptosis in cerebral vascular smooth muscle cells: possible relation to neurodegenerative diseases and strokes. Brain Res. Bull. 62 101–106.

    Not in our library10.1016/j.brainresbull.2003.08.011

  94. 94.

    Lin C. Y. Hsu Y. H. Lin M. H. Yang T. H. Chen H. M. Chen Y. C. (2013 ). Neurovascular abnormalities in humans and mice with Huntington’s disease. Exp. Neurol. 250 20–30.

    Not in our library10.1016/j.expneurol.2013.08.019

  95. 95.

    Lin S. L. Liao A. Y. Yeh S. J. Lin J. Y. (2015 ). The analysis of cardio-respiratory signals and cerebral autoregulation based on CO2 reactivity with healthy subjects and Parkinson’s patients. Technol. Health Care 24(Suppl. 1), S195–S203.

    Not in our library10.3233/thc-151069

  96. 96.

    Liu Y. Zhao H. Li H. Kalyanaraman B. Nicolosi A. C. Gutterman D. D. (2003 ). Mitochondrial sources of H2O2 generation play a key role in flow-mediated dilation in human coronary resistance arteries. Circ. Res. 93 573–580.

    Not in our library10.1161/01.res.0000091261.19387.ae

  97. 97.

    Lochhead J. J. McCaffrey G. Quigley C. E. Finch J. DeMarco K. M. Nametz N. (2010 ). Oxidative stress increases blood-brain barrier permeability and induces alterations in occludin during hypoxia-reoxygenation. J. Cereb. Blood Flow Metab. 30 1625–1636.

    Not in our library10.1038/jcbfm.2010.29

  98. 98.

    Lourenço C. F. Ledo A. Barbosa R. M. Laranjinha J. (2017 ). Neurovascular uncoupling in the triple transgenic model of Alzheimer’s disease: impaired cerebral blood flow response to neuronal-derived nitric oxide signaling. Exp. Neurol. 291 36–43.

    Not in our library10.1016/j.expneurol.2017.01.013

  99. 99.

    Love S. Chalmers K. Ince P. Esiri M. Attems J. Jellinger K. (2014 ). Development, appraisal, validation and implementation of a consensus protocol for the assessment of cerebral amyloid angiopathy in post-mortem brain tissue. Am. J. Neurodegener. Dis. 3 19–32.

    Not in our library

  100. 100.

    Lu L. Guo L. Gauba E. Tian J. Wang L. Tandon N. (2015 ). Transient cerebral ischemia promotes brain mitochondrial dysfunction and exacerbates cognitive impairments in young 5xFAD mice. PLoS One 10:e0144068.

    Not in our library10.1371/journal.pone.0144068

  101. 101.

    Mamelak M. (2017 ). Energy and the Alzheimer brain. Neurosci. Biobehav. Rev. 75 297–313.

    Not in our library10.1016/j.neubiorev.2017.02.001

  102. 102.

    Manczak M. Mao P. Calkins M. J. Cornea A. Reddy A. P. Murphy M. P. (2010 ). Mitochondria-targeted antioxidants protect against amyloid-beta toxicity in Alzheimer’s disease neurons. J. Alzheimers Dis. 20(Suppl. 2), S609–S631.

    Not in our library10.3233/jad-2010-100564

  103. 103.

    Matsumoto T. Kobayashi T. Wachi H. Seyama Y. Kamata K. (2007 ). Vascular NAD(P)H oxidase mediates endothelial dysfunction in basilar arteries from Otsuka Long-Evans Tokushima Fatty (OLETF) rats. Atherosclerosis 192 15–24.

    Not in our library10.1016/j.atherosclerosis.2006.06.005

  104. 104.

    Matsuno K. Yamada H. Iwata K. Jin D. Katsuyama M. Matsuki M. (2005 ). Nox1 is involved in angiotensin II-mediated hypertension: a study in Nox1-deficient mice. Circulation 112 2677–2685.

    Not in our library10.1161/circulationaha.105.573709

  105. 105.

    Mayhan W. G. Arrick D. M. Sharpe G. M. Sun H. (2008 ). Age-related alterations in reactivity of cerebral arterioles: role of oxidative stress. Microcirculation 15 225–236.

    Not in our library10.1080/10739680701641421

  106. 106.

    Mergenthaler P. Lindauer U. Dienel G. A. Meisel A. (2013 ). Sugar for the brain: the role of glucose in physiological and pathological brain function. Trends Neurosci. 36 587–597.

    Not in our library10.1016/j.tins.2013.07.001

  107. 107.

    Mertens S. Noll T. Spahr R. Krutzfeldt A. Piper H. M. (1990 ). Energetic response of coronary endothelial cells to hypoxia. Am. J. Physiol. 258(3 Pt 2), H689–H694.

    Not in our library10.1152/ajpheart.1990.258.3.h689

  108. 108.
    Mitochondrial Oxidative Stress, Mitochondrial DNA Damage and Their Role in Age-Related Vascular Dysfunction · 2015
    No notice
  109. 109.

    Miller A. A. Budzyn K. Sobey C. G. (2010a ). Vascular dysfunction in cerebrovascular disease: mechanisms and therapeutic intervention. Clin. Sci. 119 1–17.

    Not in our library10.1042/cs20090649

  110. 110.

    Miller A. A. De Silva T. M. Judkins C. P. Diep H. Drummond G. R. Sobey C. G. (2010b ). Augmented superoxide production by Nox2-containing NADPH oxidase causes cerebral artery dysfunction during hypercholesterolemia. Stroke 41 784–789.

    Not in our library10.1161/strokeaha.109.575365

  111. 111.

    Miller A. A. Drummond G. R. De Silva T. M. Mast A. E. Hickey H. Williams J. P. (2009 ). NADPH oxidase activity is higher in cerebral versus systemic arteries of four animal species: role of Nox2. Am. J. Physiol. Heart Circ. Physiol. 296 H220–H225.

    Not in our library10.1152/ajpheart.00987.2008

  112. 112.

    Miller A. A. Drummond G. R. Schmidt H. H. Sobey C. G. (2005 ). NADPH oxidase activity and function are profoundly greater in cerebral versus systemic arteries. Circ. Res. 97 1055–1062.

    Not in our library10.1161/01.res.0000189301.10217.87

  113. 113.

    Montagne A. Barnes S. R. Sweeney M. D. Halliday M. R. Sagare A. P. Zhao Z. (2015 ). Blood-brain barrier breakdown in the aging human hippocampus. Neuron 85 296–302.

    Not in our library10.1016/j.neuron.2014.12.032

  114. 114.

    Moon G. J. Kim S. J. Cho Y. H. Ryoo S. Bang O. Y. (2014 ). Antioxidant effects of statins in patients with atherosclerotic cerebrovascular disease. J. Clin. Neurol. 10 140–147.

    Not in our library10.3988/jcn.2014.10.2.140

  115. 115.

    Mooradian A. D. (1988 ). Effect of aging on the blood-brain barrier. Neurobiol. Aging 9 31–39.

    Not in our library10.1016/s0197-4580(88)80013-7

  116. 116.

    Morato M. Reina-Couto M. Pinho D. Albino-Teixeira A. Sousa T. (2017 ). “Regulation of the renin-angiotensin-aldosterone system by reactive oxygen species,” in Renin-Angiotensin System - Past, Present and Future, ed. Tolekova A. (Rijeka: InTech).

    Not in our library

  117. 117.

    Moreira P. I. Duarte A. I. Santos M. S. Rego A. C. Oliveira C. R. (2009 ). An integrative view of the role of oxidative stress, mitochondria and insulin in Alzheimer’s disease. J. Alzheimers Dis. 16 741–761.

    Not in our library10.3233/jad-2009-0972

  118. 118.

    Munson J. M. Fried L. Rowson S. A. Bonner M. Y. Karumbaiah L. Diaz B. (2012 ). Anti-invasive adjuvant therapy with imipramine blue enhances chemotherapeutic efficacy against glioma. Sci. Transl. Med. 4:127ra136.

    Not in our library10.1126/scitranslmed.3003016

  119. 119.

    Nelson A. R. Sweeney M. D. Sagare A. P. Zlokovic B. V. (2016 ). Neurovascular dysfunction and neurodegeneration in dementia and Alzheimer’s disease. Biochim. Biophys. Acta 1862 887–900.

    Not in our library10.1016/j.bbadis.2015.12.016

  120. 120.

    Nunomura A. Hofer T. Moreira P. I. Castellani R. J. Smith M. A. Perry G. (2009 ). RNA oxidation in Alzheimer disease and related neurodegenerative disorders. Acta Neuropathol. 118 151–166.

    Not in our library10.1007/s00401-009-0508-1

  121. 121.

    Ogunshola O. O. Antoniou X. (2009 ). Contribution of hypoxia to Alzheimer’s disease: is HIF-1alpha a mediator of neurodegeneration? Cell. Mol. Life Sci. 66 3555–3563.

    Not in our library10.1007/s00018-009-0141-0

  122. 122.

    Ohta S. Meyer E. Thompson C. J. Gjedde A. (1992 ). Oxygen consumption of the living human brain measured after a single inhalation of positron emitting oxygen. J. Cereb. Blood Flow Metab. 12 179–192.

    Not in our library10.1038/jcbfm.1992.28

  123. 123.

    Oldendorf W. H. Cornford M. E. Brown W. J. (1976 ). The large apparent metabolic work capacity of the blood-brain barrier. Trans. Am. Neurol. Assoc. 101 157–160.

    Not in our library

  124. 124.
    Cellular and molecular mechanisms of mitochondrial function · 2012
    No notice
  125. 125.

    Palmer J. C. Tayler H. M. Love S. (2013 ). Endothelin-converting enzyme-1 activity, endothelin-1 production, and free radical-dependent vasoconstriction in Alzheimer’s disease. J. Alzheimers Dis. 36 577–587.

    Not in our library10.3233/jad-130383

  126. 126.

    Park L. Anrather J. Girouard H. Zhou P. Iadecola C. (2007 ). Nox2-derived reactive oxygen species mediate neurovascular dysregulation in the aging mouse brain. J. Cereb. Blood Flow Metab. 27 1908–1918.

    Not in our library10.1038/sj.jcbfm.9600491

  127. 127.

    Park L. Anrather J. Zhou P. Frys K. Pitstick R. Younkin S. (2005 ). NADPH-oxidase-derived reactive oxygen species mediate the cerebrovascular dysfunction induced by the amyloid beta peptide. J. Neurosci. 25 1769–1777.

    Not in our library10.1523/jneurosci.5207-04.2005

  128. 128.

    Park L. Anrather J. Zhou P. Frys K. Wang G. Iadecola C. (2004 ). Exogenous NADPH increases cerebral blood flow through NADPH oxidase-dependent and -independent mechanisms. Arterioscler. Thromb. Vasc. Biol. 24 1860–1865.

    Not in our library10.1161/01.atv.0000142446.75898.44

  129. 129.

    Park L. Wang G. Moore J. Girouard H. Zhou P. Anrather J. (2014 ). The key role of transient receptor potential melastatin-2 channels in amyloid-beta-induced neurovascular dysfunction. Nat. Commun. 5:5318.

    Not in our library10.1038/ncomms6318

  130. 130.

    Park L. Wang G. Zhou P. Zhou J. Pitstick R. Previti M. L. (2011 ). Scavenger receptor CD36 is essential for the cerebrovascular oxidative stress and neurovascular dysfunction induced by amyloid-beta. Proc. Natl. Acad. Sci. U.S.A. 108 5063–5068.

    Not in our library10.1073/pnas.1015413108

  131. 131.

    Park L. Zhou P. Pitstick R. Capone C. Anrather J. Norris E. H. (2008 ). Nox2-derived radicals contribute to neurovascular and behavioral dysfunction in mice overexpressing the amyloid precursor protein. Proc. Natl. Acad. Sci. U.S.A. 105 1347–1352.

    Not in our library10.1073/pnas.0711568105

  132. 132.

    Pendyala S. Usatyuk P. V. Gorshkova I. A. Garcia J. G. Natarajan V. (2009 ). Regulation of NADPH oxidase in vascular endothelium: the role of phospholipases, protein kinases, and cytoskeletal proteins. Antioxid. Redox Signal. 11 841–860.

    Not in our library10.1089/ars.2008.2231

  133. 133.

    Perry B. N. Govindarajan B. Bhandarkar S. S. Knaus U. G. Valo M. Sturk C. (2006 ). Pharmacologic blockade of angiopoietin-2 is efficacious against model hemangiomas in mice. J. Invest. Dermatol. 126 2316–2322.

    Not in our library10.1038/sj.jid.5700413

  134. 134.

    Pimentel-Coelho P. M. Rivest S. (2012 ). The early contribution of cerebrovascular factors to the pathogenesis of Alzheimer’s disease. Eur. J. Neurosci. 35 1917–1937.

    Not in our library10.1111/j.1460-9568.2012.08126.x

  135. 135.

    Pung Y. F. Rocic P. Murphy M. P. Smith R. A. Hafemeister J. Ohanyan V. (2012 ). Resolution of mitochondrial oxidative stress rescues coronary collateral growth in Zucker obese fatty rats. Arterioscler. Thromb. Vasc. Biol. 32 325–334.

    Not in our library10.1161/atvbaha.111.241802

  136. 136.

    Quintero M. Colombo S. L. Godfrey A. Moncada S. (2006 ). Mitochondria as signaling organelles in the vascular endothelium. Proc. Natl. Acad. Sci. U.S.A. 103 5379–5384.

    Not in our library10.1073/pnas.0601026103

  137. 137.

    Ray R. Murdoch C. E. Wang M. Santos C. X. Zhang M. Alom-Ruiz S. (2011 ). Endothelial Nox4 NADPH oxidase enhances vasodilatation and reduces blood pressure in vivo. Arterioscler. Thromb. Vasc. Biol. 31 1368–1376.

    Not in our library10.1161/atvbaha.110.219238

  138. 138.

    Richter C. Kass G. E. (1991 ). Oxidative stress in mitochondria: its relationship to cellular Ca2+ homeostasis, cell death, proliferation, and differentiation. Chem. Biol. Interact. 77 1–23.

    Not in our library10.1016/0009-2797(91)90002-o

  139. 139.

    Ricquier D. Bouillaud F. (2000 ). Mitochondrial uncoupling proteins: from mitochondria to the regulation of energy balance. J. Physiol. 529(Pt 1), 3–10.

    Not in our library10.1111/j.1469-7793.2000.00003.x

  140. 140.

    Rodriguez-Cuenca S. Cocheme H.M. Logan A. Abakumova I. Prime T.A. Rose C. (2010 ). Consequences of long-term oral administration of the mitochondria-targeted antioxidant MitoQ to wild-type mice. Free Radic. Biol. Med. 48 161–172.

    Not in our library10.1016/j.freeradbiomed.2009.10.039

  141. 141.

    Rojo A. I. Innamorato N. G. Martin-Moreno A. M. De Ceballos M. L. Yamamoto M. Cuadrado A. (2010 ). Nrf2 regulates microglial dynamics and neuroinflammation in experimental Parkinson’s disease. Glia 58 588–598.

    Not in our library10.1002/glia.20947

  142. 142.

    Ronnett G. V. Ramamurthy S. Kleman A. M. Landree L. E. Aja S. (2009 ). AMPK in the brain: its roles in energy balance and neuroprotection. J. Neurochem. 109(Suppl. 1), 17–23.

    Not in our library10.1111/j.1471-4159.2009.05916.x

  143. 143.

    Rutkai I. Dutta S. Katakam P. V. Busija D. W. (2015 ). Dynamics of enhanced mitochondrial respiration in female compared with male rat cerebral arteries. Am. J. Physiol. Heart Circ. Physiol. 309 H1490–H1500.

    Not in our library10.1152/ajpheart.00231.2015

  144. 144.

    Sahoo S. Meijles D. N. Pagano P. J. (2016 ). NADPH oxidases: key modulators in aging and age-related cardiovascular diseases? Clin. Sci. 130 317–335.

    Not in our library10.1042/cs20150087

  145. 145.

    Schreibelt G. Kooij G. Reijerkerk A. van Doorn R. Gringhuis S. I. van der Pol S. (2007 ). Reactive oxygen species alter brain endothelial tight junction dynamics via RhoA, PI3 kinase, and PKB signaling. FASEB J. 21 3666–3676.

    Not in our library10.1096/fj.07-8329com

  146. 146.

    Shah G. N. Morofuji Y. Banks W. A. Price T. O. (2013 ). High glucose-induced mitochondrial respiration and reactive oxygen species in mouse cerebral pericytes is reversed by pharmacological inhibition of mitochondrial carbonic anhydrases: implications for cerebral microvascular disease in diabetes. Biochem. Biophys. Res. Commun. 440 354–358.

    Not in our library10.1016/j.bbrc.2013.09.086

  147. 147.

    Shah Z. A. Li R. C. Thimmulappa R. K. Kensler T. W. Yamamoto M. Biswal S. (2007 ). Role of reactive oxygen species in modulation of Nrf2 following ischemic reperfusion injury. Neuroscience 147 53–59.

    Not in our library10.1016/j.neuroscience.2007.02.066

  148. 148.

    Sheu S. S. Nauduri D. Anders M. W. (2006 ). Targeting antioxidants to mitochondria: a new therapeutic direction. Biochim. Biophys. Acta 1762 256–265.

    Not in our library10.1016/j.bbadis.2005.10.007

  149. 149.

    Skoog I. Gustafson D. (2006 ). Update on hypertension and Alzheimer’s disease. Neurol. Res. 28 605–611.

    Not in our library10.1179/016164106x130506

  150. 150.

    Smith R. A. Adlam V. J. Blaikie F. H. Manas A. R. Porteous C. M. James A. M. (2008 ). Mitochondria-targeted antioxidants in the treatment of disease. Ann. N. Y. Acad. Sci. 1147 105–111.

    Not in our library10.1196/annals.1427.003

  151. 151.

    Smith R. A. Hartley R. C. Murphy M. P. (2011 ). Mitochondria-targeted small molecule therapeutics and probes. Antioxid. Redox Signal. 15 3021–3038.

    Not in our library10.1089/ars.2011.3969

  152. 152.

    Smith R. A. Murphy M. P. (2011 ). Mitochondria-targeted antioxidants as therapies. Discov. Med. 11 106–114.

    Not in our library

  153. 153.

    Spahr R. Krutzfeldt A. Mertens S. Siegmund B. Piper H. M. (1989 ). Fatty acids are not an important fuel for coronary microvascular endothelial cells. Mol. Cell. Biochem. 88 59–64.

    Not in our library10.1007/bf00223424

  154. 154.

    Staiculescu M. C. Foote C. Meininger G. A. Martinez-Lemus L. A. (2014 ). The role of reactive oxygen species in microvascular remodeling. Int. J. Mol. Sci. 15 23792–23835.

    Not in our library10.3390/ijms151223792

  155. 155.

    St-Amour I. Aube B. Rieux M. Cicchetti F. (2015 ). Targeting cerebrovascular impairments in Huntington’s disease: a novel treatment perspective. Neurodegener. Dis. Manage. 5 389–393.

    Not in our library10.2217/nmt.15.41

  156. 156.

    Steinman J. Koletar M. M. Stefanovic B. Sled J. G. (2017 ). 3D morphological analysis of the mouse cerebral vasculature: comparison of in vivo and ex vivo methods. PLoS One 12:e0186676.

    Not in our library10.1371/journal.pone.0186676

  157. 157.

    Sun Y. Lee R. Chen Y. Collinson S. Thakor N. Bezerianos A. (2015 ). Progressive gender differences of structural brain networks in healthy adults: a longitudinal, diffusion tensor imaging study. PLoS One 10:e0118857.

    Not in our library10.1371/journal.pone.0118857

  158. 158.

    Sweeney M. D. Sagare A. P. Zlokovic B. V. (2015 ). Cerebrospinal fluid biomarkers of neurovascular dysfunction in mild dementia and Alzheimer’s disease. J. Cereb. Blood Flow Metab. 35 1055–1068.

    Not in our library10.1038/jcbfm.2015.76

  159. 159.

    Takac I. Schroder K. Brandes R. P. (2012 ). The Nox family of NADPH oxidases: friend or foe of the vascular system? Curr. Hypertens. Rep. 14 70–78.

    Not in our library10.1007/s11906-011-0238-3

  160. 160.
    Mitochondria, endothelial cell function, and vascular diseases · 2014
    No notice
  161. 161.

    Tarantini S. Fulop G. A. Kiss T. Farkas E. Zolei-Szenasi D. Galvan V. (2017a ). Demonstration of impaired neurovascular coupling responses in TG2576 mouse model of Alzheimer’s disease using functional laser speckle contrast imaging. Geroscience [Epub ahead of print].

    Not in our library10.1007/s11357-017-9980-z

  162. 162.

    Tarantini S. Tran C. H. T. Gordon G. R. Ungvari Z. Csiszar A. (2017b ). Impaired neurovascular coupling in aging and Alzheimer’s disease: contribution of astrocyte dysfunction and endothelial impairment to cognitive decline. Exp. Gerontol. 94 52–58.

    Not in our library10.1016/j.exger.2016.11.004

  163. 163.

    Tayarani I. Chaudiere J. Lefauconnier J. M. Bourre J. M. (1987 ). Enzymatic protection against peroxidative damage in isolated brain capillaries. J. Neurochem. 48 1399–1402.

    Not in our library10.1111/j.1471-4159.1987.tb05677.x

  164. 164.

    Togliatto G. Lombardo G. Brizzi M. F. (2017 ). The future challenge of reactive oxygen species (ROS) in hypertension: from bench to bed side. Int. J. Mol. Sci. 18:E1988.

    Not in our library10.3390/ijms18091988

  165. 165.

    Tong X. K. Nicolakakis N. Kocharyan A. Hamel E. (2005 ). Vascular remodeling versus amyloid beta-induced oxidative stress in the cerebrovascular dysfunctions associated with Alzheimer’s disease. J. Neurosci. 25 11165–11174.

    Not in our library10.1523/jneurosci.4031-05.2005

  166. 166.

    Toth P. Tarantini S. Tucsek Z. Ashpole N. M. Sosnowska D. Gautam T. (2014 ). Resveratrol treatment rescues neurovascular coupling in aged mice: role of improved cerebromicrovascular endothelial function and downregulation of NADPH oxidase. Am. J. Physiol. Heart Circ. Physiol. 306 H299–H308.

    Not in our library10.1152/ajpheart.00744.2013

  167. 167.

    Ungvari Z. Labinskyy N. Gupte S. Chander P. N. Edwards J. G. Csiszar A. (2008 ). Dysregulation of mitochondrial biogenesis in vascular endothelial and smooth muscle cells of aged rats. Am. J. Physiol. Heart Circ. Physiol. 294 H2121–H2128.

    Not in our library10.1152/ajpheart.00012.2008

  168. 168.

    Ungvari Z. Orosz Z. Labinskyy N. Rivera A. Xiangmin Z. Smith K. (2007 ). Increased mitochondrial H2O2 production promotes endothelial NF-kappaB activation in aged rat arteries. Am. J. Physiol. Heart Circ. Physiol. 293 H37–H47.

    Not in our library10.1152/ajpheart.01346.2006

  169. 169.

    Vaas M. Deistung A. Reichenbach J. R. Keller A. Kipar A. Klohs J. (2017 ). Vascular and tissue changes of magnetic susceptibility in the mouse brain after transient cerebral ischemia. Transl. Stroke Res. [Epub ahead of print].

    Not in our library10.1007/s12975-017-0591-x

  170. 170.

    Valko M. Leibfritz D. Moncol J. Cronin M. T. Mazur M. Telser J. (2007 ). Free radicals and antioxidants in normal physiological functions and human disease. Int. J. Biochem. Cell Biol. 39 44–84.

    Not in our library10.1016/j.biocel.2006.07.001

  171. 171.

    Vargas M. R. Johnson J. A. (2009 ). The Nrf2-ARE cytoprotective pathway in astrocytes. Expert Rev. Mol. Med. 11:e17.

    Not in our library10.1017/s1462399409001094

  172. 172.

    Vergeade A. Mulder P. Vendeville-Dehaudt C. Estour F. Fortin D. Ventura-Clapier R. (2010 ). Mitochondrial impairment contributes to cocaine-induced cardiac dysfunction: prevention by the targeted antioxidant MitoQ. Free Radic. Biol. Med. 49 748–756.

    Not in our library10.1016/j.freeradbiomed.2010.05.024

  173. 173.

    Wang M. Zhang J. Walker S. J. Dworakowski R. Lakatta E. G. Shah A. M. (2010 ). Involvement of NADPH oxidase in age-associated cardiac remodeling. J. Mol. Cell. Cardiol. 48 765–772.

    Not in our library10.1016/j.yjmcc.2010.01.006

  174. 174.

    Wang Y. Zang Q. S. Liu Z. Wu Q. Maass D. Dulan G. (2011 ). Regulation of VEGF-induced endothelial cell migration by mitochondrial reactive oxygen species. Am. J. Physiol. Cell Physiol. 301 C695–C704.

    Not in our library10.1152/ajpcell.00322.2010

  175. 175.

    Wenzel P. Schuhmacher S. Kienhofer J. Muller J. Hortmann M. Oelze M. (2008 ). Manganese superoxide dismutase and aldehyde dehydrogenase deficiency increase mitochondrial oxidative stress and aggravate age-dependent vascular dysfunction. Cardiovasc. Res. 80 280–289.

    Not in our library10.1093/cvr/cvn182

  176. 176.

    Wevers N. R. de Vries H. E. (2016 ). Morphogens and blood-brain barrier function in health and disease. Tissue Barriers 4:e1090524.

    Not in our library10.1080/21688370.2015.1090524

  177. 177.

    Yan W. Wang H. D. Hu Z. G. Wang Q. F. Yin H. X. (2008 ). Activation of Nrf2-ARE pathway in brain after traumatic brain injury. Neurosci. Lett. 431 150–154.

    Not in our library10.1016/j.neulet.2007.11.060

  178. 178.

    Zhang R. Ran H. H. Cai L. L. Zhu L. Sun J. F. Peng L. (2014 ). Simulated microgravity-induced mitochondrial dysfunction in rat cerebral arteries. FASEB J. 28 2715–2724.

    Not in our library10.1096/fj.13-245654

  179. 179.

    Zlokovic B. V. (2008 ). The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 57 178–201.

    Not in our library10.1016/j.neuron.2008.01.003

  180. 180.

    Zlokovic B. V. (2011 ). Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders. Nat. Rev. Neurosci. 12 723–738.

    Not in our library10.1038/nrn3114

Cited by papers we hold 3

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.